Department of Nuclear Medicine, Guizhou Provincial People's Hospital, Guizhou, China.
Department of Intervention and Vascular Surgery, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou Cancer Medical Center, Suzhou, China.
Eur J Clin Invest. 2018 May;48(5):e12917. doi: 10.1111/eci.12917. Epub 2018 Mar 24.
The platelet-to-lymphocyte ratio (PLR) has been found to predict clinical outcomes in borderline ovarian tumours and the other genital neoplasms. However, its prognostic value in patients with ovarian cancer remains controversial. The aim of this study was to assess its prognostic value in ovarian cancer.
We searched MEDLINE, EMBASE and the Cochrane databases to identify studies evaluating the prognostic significance of pretreatment PLR in ovarian cancer. The end points were overall survival (OS) and progression-free survival (PFS). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using fixed-effects/random-effects models.
A total of 11 studies comprising 3574 patients with ovarian cancer were included. The random-effects meta-analysis demonstrated that patients with elevated PLR had shorter OS (HR: 1.48, 95% CI: 1.24-1.76, P < .001) and PFS (HR: 1.38, 95% CI: 1.17-1.63, P < .001). The negative prognostic impact of high PLR on OS and PFS remained substantial in Asian populations, patients with PLR ≥ 200 and studies with NOS score ≥ 7.
Elevated pretreatment PLR could be an unfavourable prognostic factor for clinical outcomes in patients with ovarian cancer.
血小板与淋巴细胞比值（PLR）已被发现可预测交界性卵巢肿瘤和其他生殖系统肿瘤的临床结局。然而，其在卵巢癌患者中的预后价值仍存在争议。本研究旨在评估其在卵巢癌中的预后价值。
我们检索了 MEDLINE、EMBASE 和 Cochrane 数据库，以确定评估卵巢癌患者治疗前 PLR 预后意义的研究。终点是总生存期（OS）和无进展生存期（PFS）。使用固定效应/随机效应模型计算合并风险比（HR）及其 95%置信区间（CI）。
共纳入 11 项研究，包含 3574 例卵巢癌患者。随机效应荟萃分析表明，PLR 升高的患者 OS 更短（HR：1.48，95%CI：1.24-1.76，P<0.001）和 PFS 更短（HR：1.38，95%CI：1.17-1.63，P<0.001）。在亚洲人群、PLR≥200 的患者和 NOS 评分≥7 的研究中，高 PLR 对 OS 和 PFS 的负性预后影响仍然较大。
治疗前 PLR 升高可能是卵巢癌患者临床结局的不利预后因素。
